Search alternatives:
significant effect » significant impact (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
effect release » effective release (Expand Search), effect repeated (Expand Search), direct release (Expand Search)
Showing 61 - 80 results of 21,940 for search '(( significantly ((lower decrease) OR (larger decrease)) ) OR ( significant effect release ))', query time: 0.29s Refine Results
  1. 61
    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction.

    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is).

    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

    Published 2023
    Save to List
    Saved in:
  3. 63
    Effect of silicon on osteoclastic bone resorption, assayed as released CTX-I.

    Effect of silicon on osteoclastic bone resorption, assayed as released CTX-I. by Catarina Magnusson (19852406)

    Published 2024
    Save to List
    Saved in:
  4. 64
    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in the N-deficient treatment.

    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

    Published 2023
    Save to List
    Saved in:
  5. 65
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 66
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 67
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 68
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 69
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 70
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 71
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 72
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 73
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 74
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 75
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 76
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 77
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 78
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 79
    Comparison of sociodemographic measures between controls and those with anhedonia in the ABCD 4.0 release, excluding ABCD 1.0 release, sub-sample.

    Comparison of sociodemographic measures between controls and those with anhedonia in the ABCD 4.0 release, excluding ABCD 1.0 release, sub-sample. by Yi Zhou (2723)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 80
    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups.

    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups. by Yunmeng Da (707943)

    Published 2024
    Save to List
    Saved in:

Search Tools: